Finally, a patient with the TPM3–NTRK1 fusion selected larotrectinib, a TRK inhibitor, as second-line treatment following the recommendation of the molecular tumor board and showed a good response; however, treatment was discontinued due to an infection and hepatic reserve deterioration. Here, TPM3 is linked to neoplasm.